Societal costs of sepsis in the Netherlands
Authors' conclusion
Sepsis and its complications pose a substantial disease and indirect economic burden to the Netherlands, with an indirect economic burden due to production loss that is potentially larger than the burden due to coronary heart disease or stroke.
Study context
- Population
- Sepsis in the Netherlands (national population)
- Outcome
- Annual disease burden (QALYs) and indirect economic costs (productivity loss, increased healthcare use post-sepsis) of sepsis
- Follow-up
- Annual
Methodological detailsmodelling based on literature and Statistics Netherlands data, sensitivity analysis (baseline, low, high burden)
- Modelling based on literature and Statistics Netherlands data
- Sensitivity analysis (baseline, low, high burden)
Main finding
As reported in the abstract
Annual societal burden of sepsis, baseline (low-high burden) estimate
- Annual disease burden, Quality-adjusted Life Years (QALYs) (low-high burden 24,398-96,244)
- 57,304
- QALYs due to mortality (23,166-31,577)
- 26,898
- QALYs due to Quality of Life (QoL) decrease post-sepsis (1232-64,667)
- 30,406
- Indirect economic burden, friction cost approach (€147.1-610.7 million)
- €416.1 million
- Indirect economic burden, human capital method (€0.4-5.7 billion)
- €3.1 billion
- Combined disease and indirect economic burden, friction method
- €3.8 billion
- Combined disease and indirect economic burden, human capital method
- €6.5 billion
Original publication
Societal costs of sepsis in the Netherlands. Crit Care. Published 22 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →